FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991232904> ?p ?o ?g. }

• W1991232904 endingPage "233" @default.
• W1991232904 startingPage "227" @default.
• W1991232904 abstract "Infections in intensive care unit (ICU) patients like severe pneumonia, e.g. nosocomial (NP) and community-acquired pneumonia (CAP), or septicemia must be treated promptly and effectively because of the ensuing high mortality. Treatment is thus empirical and starts before the results of microbiological cultures are known. The risk factors affecting mortality include severity of illness, virulence of etiologic pathogens and the use of inappropriate antibiotic therapy. Several studies have shown that modifying initially inadequate therapy, according to microbiological results, does not result in a better outcome. Due to this, antibiotic treatment requires agents which have an appropriate spectrum covering the likely pathogens causing these infections. In critically ill patients, the need for empirical first-line treatment covering a broad spectrum of Gram-negative and Gram-positive bacteria, as recommended in international guidelines (e.g. those of the American Thoracic Society or the Infectious Diseases Society of America), is justified in the presence of resistant organisms commonly documented in these patients. To choose an appropriate, initial antibiotic regimen, local and national resistance data have to be considered. With respect to new German resistance trends in Gram-negative and Gram-positive bacteria, the Paul Ehrlich Society of Chemotherapy has recently published guidelines for the treatment of infections in hospitalized patients. Especially in ICU patients with severe pneumonia (NP or CAP) or septicemia and risk factors like underlying diseases, antibiotic pretreatment or mechanical ventilation, agents with an appropriate spectrum encompassing Pseudomonas aeruginosa as well as other Gram-negative bacteria like Escherichia coli, Klebsiella spp., Enterobacter spp. and Gram-positive bacteria (e.g. Staphylococcus aureus, pneumococci and streptococci) are recommended as treatment of choice. Combination therapy with an anti-pseudomonal beta-lactam and a fluoroquinolone or an aminoglycoside are recommended for these patients to provide the necessary spectrum of activity and to prevent the emergence of resistant organisms. On the other hand, clinical trials and meta-analyses have shown the efficacy, tolerability and cost-effectiveness of monotherapy regimens even in critically ill and immunocompromised patients.Appropriate beta-lactam antibiotics recommended in international and German guidelines for the treatment of severe CAP, NP and septicemia, either as monotherapy or as combination therapy, are the 4th generation cephalosporin cefepime, the carbapenems imipenem and meropenem, and the acylamino-beta-lactamase inhibitor combination piperacillin-tazobactam." @default.
• W1991232904 created "2016-06-24" @default.
• W1991232904 creator A5072278635 @default.
• W1991232904 date "2005-01-01" @default.
• W1991232904 modified "2023-10-05" @default.
• W1991232904 title "Current Guidelines for the Treatment of Severe Pneumonia and Sepsis" @default.
• W1991232904 cites W130264434 @default.
• W1991232904 cites W1584523128 @default.
• W1991232904 cites W1966375310 @default.
• W1991232904 cites W1985370165 @default.
• W1991232904 cites W1999260116 @default.
• W1991232904 cites W2022890701 @default.
• W1991232904 cites W2024129386 @default.
• W1991232904 cites W2061194988 @default.
• W1991232904 cites W2077608492 @default.
• W1991232904 cites W2087692099 @default.
• W1991232904 cites W2091493523 @default.
• W1991232904 cites W2097563038 @default.
• W1991232904 cites W2123324969 @default.
• W1991232904 cites W2130141864 @default.
• W1991232904 cites W2142230428 @default.
• W1991232904 cites W2148052607 @default.
• W1991232904 cites W2148706534 @default.
• W1991232904 cites W2158350453 @default.
• W1991232904 cites W2315779791 @default.
• W1991232904 cites W2321907083 @default.
• W1991232904 cites W2398756509 @default.
• W1991232904 cites W2413935329 @default.
• W1991232904 cites W4249764287 @default.
• W1991232904 doi "https://doi.org/10.1159/000087452" @default.
• W1991232904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16103664" @default.
• W1991232904 hasPublicationYear "2005" @default.
• W1991232904 type Work @default.
• W1991232904 sameAs 1991232904 @default.
• W1991232904 citedByCount "52" @default.
• W1991232904 countsByYear W19912329042012 @default.
• W1991232904 countsByYear W19912329042013 @default.
• W1991232904 countsByYear W19912329042014 @default.
• W1991232904 countsByYear W19912329042015 @default.
• W1991232904 countsByYear W19912329042016 @default.
• W1991232904 countsByYear W19912329042017 @default.
• W1991232904 countsByYear W19912329042018 @default.
• W1991232904 countsByYear W19912329042019 @default.
• W1991232904 countsByYear W19912329042021 @default.
• W1991232904 countsByYear W19912329042023 @default.
• W1991232904 crossrefType "journal-article" @default.
• W1991232904 hasAuthorship W1991232904A5072278635 @default.
• W1991232904 hasConcept C104317684 @default.
• W1991232904 hasConcept C126322002 @default.
• W1991232904 hasConcept C177713679 @default.
• W1991232904 hasConcept C2776376669 @default.
• W1991232904 hasConcept C2776933286 @default.
• W1991232904 hasConcept C2777637488 @default.
• W1991232904 hasConcept C2777914695 @default.
• W1991232904 hasConcept C2778384902 @default.
• W1991232904 hasConcept C2778983983 @default.
• W1991232904 hasConcept C501593827 @default.
• W1991232904 hasConcept C523546767 @default.
• W1991232904 hasConcept C54355233 @default.
• W1991232904 hasConcept C547475151 @default.
• W1991232904 hasConcept C55493867 @default.
• W1991232904 hasConcept C71924100 @default.
• W1991232904 hasConcept C86803240 @default.
• W1991232904 hasConcept C89423630 @default.
• W1991232904 hasConcept C94665300 @default.
• W1991232904 hasConceptScore W1991232904C104317684 @default.
• W1991232904 hasConceptScore W1991232904C126322002 @default.
• W1991232904 hasConceptScore W1991232904C177713679 @default.
• W1991232904 hasConceptScore W1991232904C2776376669 @default.
• W1991232904 hasConceptScore W1991232904C2776933286 @default.
• W1991232904 hasConceptScore W1991232904C2777637488 @default.
• W1991232904 hasConceptScore W1991232904C2777914695 @default.
• W1991232904 hasConceptScore W1991232904C2778384902 @default.
• W1991232904 hasConceptScore W1991232904C2778983983 @default.
• W1991232904 hasConceptScore W1991232904C501593827 @default.
• W1991232904 hasConceptScore W1991232904C523546767 @default.
• W1991232904 hasConceptScore W1991232904C54355233 @default.
• W1991232904 hasConceptScore W1991232904C547475151 @default.
• W1991232904 hasConceptScore W1991232904C55493867 @default.
• W1991232904 hasConceptScore W1991232904C71924100 @default.
• W1991232904 hasConceptScore W1991232904C86803240 @default.
• W1991232904 hasConceptScore W1991232904C89423630 @default.
• W1991232904 hasConceptScore W1991232904C94665300 @default.
• W1991232904 hasIssue "5" @default.
• W1991232904 hasLocation W19912329041 @default.
• W1991232904 hasLocation W19912329042 @default.
• W1991232904 hasOpenAccess W1991232904 @default.
• W1991232904 hasPrimaryLocation W19912329041 @default.
• W1991232904 hasRelatedWork W137943344 @default.
• W1991232904 hasRelatedWork W1966814333 @default.
• W1991232904 hasRelatedWork W2003343094 @default.
• W1991232904 hasRelatedWork W2030278871 @default.
• W1991232904 hasRelatedWork W2247376599 @default.
• W1991232904 hasRelatedWork W2328228223 @default.
• W1991232904 hasRelatedWork W2358528625 @default.
• W1991232904 hasRelatedWork W2409546295 @default.
• W1991232904 hasRelatedWork W3160359428 @default.
• W1991232904 hasRelatedWork W4317611848 @default.

• next